WordNet

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 過敏性腸症候群に対するアロセトロン塩酸塩（Lotronex） alosetron hydrochloride lotronex for irritable bowel syndrome
2. 変形性関節症の初回薬物療法 initial pharmacologic therapy of osteoarthritis
3. クリンダマイシン：概要 clindamycin an overview
4. 成人における急性咽頭炎の対症療法 symptomatic treatment of acute pharyngitis in adults
5. 慢性非アレルギー性鼻炎 chronic nonallergic rhinitis

Intra-arterial Colforsin May Improve the Outcome of Patients with Aneurysmal Subarachnoid Hemorrhage: A Retrospective Study.

Suzuki S, Sato M, Ota S, Fukushima T, Ota A, Ota T, Goto K.SourceDepartment of Neurosurgery, Nippon Steel Yawata Memorial Hospital, Kitakyushu, Japan.
World neurosurgery.World Neurosurg.2011 Nov 24. [Epub ahead of print]
OBJECTIVE: Papaverine hydrochloride (PPV) has been widely used for pharmacological angioplasty to dilate spastic vessels after aneurysmal subarachnoid hemorrhage (SAH). Colforsin daropate hydrochloride (CDH) has also recently been reported to be useful for reversal of cerebral vasospasm (CV). In thi
PMID 22120553

Intra-arterial colforsin daropate for the treatment of cerebral vasospasm after aneurysmal subarachnoid hemorrhage.

Suzuki S, Ito O, Sayama T, Goto K.SourceDepartment of Neurosurgery, Nippon Steel Yawata Memorial Hospital, Yahatahigashi-ku, Kitakyushu, Japan. suzuki.s@ns.yawata-mhp.or.jp
Neuroradiology.Neuroradiology.2010 Sep;52(9):837-45. Epub 2009 Dec 2.
INTRODUCTION: Cerebral vasospasm (CV) remains a major cause of mortality and morbidity in patients with subarachnoid hemorrhage (SAH). Here, we examined the effectiveness and safety of intra-arterial injection of colforsin daropate hydrochloride (CDH).METHODS: A consecutive series of 29 patients wit
PMID 19953235

日本集中治療医学会雑誌 = Journal of the Japanese Society of Intensive Care Medicine 15(1), 73-77, 2008-01-01
NAID 10024840254

英: colforsin、
化: 塩酸コルホルシンダロパート colforsin daropate hydrochloride、コルホルシンダロパート colforsin daropate
商: アデール
関: フォルスコリン

塩酸コルホルシンダロパートはフォルスコリンの水溶性の誘導体で，cAMPを合成するアデニル酸シクラーゼ活性を直接刺激することで強心作用を示す。本薬剤0.25─0.5μg/kg/minの長時間投与効果を確認したわれわれの成績では，血圧はほとんど変化させず，心拍数はやや増加傾向，CIと1回拍出量は増加を示し，PCWPはPDEIII阻害薬ほどではないが確実に低下させている。